New hope for kids with Crohn's: drug trial targets remission
NCT ID NCT07298421
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This study tests a drug called afimkibart in 100 children aged 2 to 17 with moderate-to-severe Crohn's disease. The goal is to see if it can help children feel better and heal their gut lining. Participants will receive the drug as an IV or injection, and doctors will monitor their symptoms and inflammation over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chulalongkorn University
RECRUITINGBangkok, 10330, Thailand
-
National Taiwan University Hospital
RECRUITINGTaipei, 100, Taiwan
-
Perth Children's Hospital
RECRUITINGNedlands, Western Australia, 6009, Australia
-
Ramathibodi Hospital
RECRUITINGBangkok, Thailand
-
Royal Children's Hospital
RECRUITINGParkville, Victoria, 3052, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
afimkibart (a drug given by IV infusion or injection)
What this could lead to
If successful, this could provide a new treatment option to help children with Crohn's disease achieve remission and reduce gut inflammation.
What could go wrong
This is still an early-stage test in a small group of 100 children. The drug may not work better than existing treatments, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.